Literature DB >> 20462665

Papulopustular rosacea: prevalence and relationship to photodamage.

Maeve A McAleer1, Patricia Fitzpatrick, Frank C Powell.   

Abstract

BACKGROUND: The prevalence and pathogenesis of rosacea is uncertain. Previously, studies used varying definitions of disease and have not explored the relationship of its prevalence to ultraviolet (UV) exposure or photodamage.
OBJECTIVES: We investigated the prevalence of papulopustular rosacea (PPR) and its relationship to UV radiation exposure in 1000 randomly selected Irish individuals.
METHODS: A total of 1000 individuals (500 with low UV exposure and 500 with high UV exposure) were examined. PPR was diagnosed using a standardized definition and photodamage was assessed using a photodamage scale.
RESULTS: The prevalence of PPR was 2.7%. PPR prevalence was not significantly related to photodamage or UV exposure. LIMITATIONS: The power to compare UV exposure among those with and without PPR was limited.
CONCLUSIONS: PPR prevalence in Ireland was 2.7%. UV radiation exposure does not appear to affect the prevalence of PPR. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20462665     DOI: 10.1016/j.jaad.2009.04.024

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

Review 1.  Clinical, cellular, and molecular aspects in the pathophysiology of rosacea.

Authors:  Martin Steinhoff; Jörg Buddenkotte; Jerome Aubert; Mathias Sulk; Pawel Novak; Verena D Schwab; Christian Mess; Ferda Cevikbas; Michel Rivier; Isabelle Carlavan; Sophie Déret; Carine Rosignoli; Dieter Metze; Thomas A Luger; Johannes J Voegel
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

2.  Cigarette Smoking and Risk of Incident Rosacea in Women.

Authors:  Suyun Li; Eunyoung Cho; Aaron M Drucker; Abrar A Qureshi; Wen-Qing Li
Journal:  Am J Epidemiol       Date:  2017-07-01       Impact factor: 4.897

3.  Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

4.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

5.  A Guide to the Ingredients and Potential Benefits of Over-the-Counter Cleansers and Moisturizers for Rosacea Patients.

Authors:  Jacquelyn Levin; Richard Miller
Journal:  J Clin Aesthet Dermatol       Date:  2011-08

6.  Minocycline Extended-Release Comparison with Doxycycline for the Treatment of Rosacea: A Randomized, Head-to-Head, Clinical Trial.

Authors:  Athanasios Tsianakas; Thomas Pieber; Hilary Baldwin; Franz Feichtner; Shanavas Alikunju; Anirudh Gautam; Srinivas Shenoy; Preeti Singh; Srinivas Sidgiddi
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

7.  Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.

Authors:  Todd Williamson; Wendy Y Cheng; Nora McCormick; Francis Vekeman
Journal:  Am Health Drug Benefits       Date:  2018-04

8.  Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea.

Authors:  Ji Young Kim; Yoon Jee Kim; Beom Jin Lim; Hyo Jung Sohn; Dongyun Shin; Sang Ho Oh
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

9.  Update on the management of rosacea.

Authors:  Allison P Weinkle; Vladyslava Doktor; Jason Emer
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-07

Review 10.  Major pathophysiological correlations of rosacea: a complete clinical appraisal.

Authors:  Ravi Chandra Vemuri; Rohit Gundamaraju; Shamala Devi Sekaran; Rishya Manikam
Journal:  Int J Med Sci       Date:  2015-05-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.